Cancer-associated neochromosomes: A novel mechanism of oncogenesis

BioEssays

Volumn 31, Issue 11, 2009, Pages 1191-1200

  Garsed, Dale W ^a   Holloway, Andrew J ^a   Thomas, David M ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Neochromosome; Oncogenesis; Welldifferentiated liposarcoma

Indexed keywords

CANCER ASSOCIATED NEOCHROMOSOME; CANCER GENETICS; CARCINOGENESIS; CELL TRANSFORMATION; CENTROMERE; CHROMOSOME; CHROMOSOME REARRANGEMENT; CHROMOSOME STRUCTURE; GENE SEQUENCE; GENETIC DISORDER; HUMAN; LIPOSARCOMA; MOLECULAR MECHANICS; ONCOGENE; REVIEW; TELOMERE; WELL DIFFERENTIATED LIPOSARCOMA;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; CHROMOSOMES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DNA, SATELLITE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSARCOMA; NEOPLASMS; TELOMERE;

EID: 70549110094     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.200800208     Document Type: Review

References (58)

1. Gisselsson, D., Hoglund, M., Mertens, F., Johansson, B., Dal Cin, P., et al. The structure and dynamics of ring chromosomes in human neoplastic and non-neoplastic cells. Hum Genet 1999. 104: 315-325. (Pubitemid 29251150)
2. Ferguson-Smith, M. A. and Yates, J. R., Maternal age specific rates for chromosome aberrations and factors influencing them: report of a collaborative European study on 52 965 amniocenteses. Prenat Diagn 1984. 4: 5-44.
3. Cote, G. B., Katsantoni, A. and Deligeorgis, D., The cytogenetic and clinical implications of a ring chromosome 2. Ann Genet 1981. 24: 231-235. (Pubitemid 12239363)
4. Gisselsson, D., Chromosomal instability in cancer: causes and consequences. Atlas Genet Cytogenet Oncol Haematol 2002. 6: 141-153.
5. Tommerup, N. and Lothe, R., Constitutional ring chromosomes and tumour suppressor genes. J Med Genet 1992. 29: 879-882. (Pubitemid 23035212)
6. Gisselsson, D., Palsson, E., Hoglund, M., Domanski, H., Mertens, F., et al. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer 2002. 33: 133-140. (Pubitemid 34052494)
7. Sirvent, N., Maire, G. and Pedeutour, F., Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003. 37: 1-19. (Pubitemid 36417917)
8. Heim, S., Mandahl, N., Rydholm, A., Willen, H. and Mitelman, F., Different karyotypic features characterize different clinico-pathologic subgroups of benign lipogenic tumors. Int J Cancer 1988. 42: 863-867. (Pubitemid 19012915)
9. Sandberg, A. A., Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 2004. 155: 1-24. (Pubitemid 39446608)
10. Fletcher, C. D., Akerman, M., Dal Cin, P., de Wever, I., Mandahl, N., et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol 1996. 148: 623-630. (Pubitemid 26056746)
11. Iwasaki, H., Ohjimi, Y., Ishiguro, M., Isayama, T., Fujita, C., et al. Supernumerary ring chromosomes and nuclear blebs in some low-grade malignant soft tissue tumours: atypical lipomatous tumours and dermatofibrosarcoma protuberans. Virchows Arch 1998. 432: 521-528. (Pubitemid 28297559)
12. Pedeutour, F., Forus, A., Coindre, J. M., Berner, J. M., Nicolo, G., et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999. 24: 30-41. (Pubitemid 28544460)
13. Persson, F., Olofsson, A., Sjogren, H., Chebbo, N., Nilsson, B., et al. Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. Cancer Lett 2008. 260: 37-47.
14. Italiano, A., Bianchini, L., Keslair, F., Bonnafous, S., Cardot-Leccia, N., et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008. 122: 2233-2241. (Pubitemid 351542325)
15. Sawyer, J. R., Rowe, R. A., Hassed, S. J. and Cunniff, C., Highresolution cytogenetic characterization of telomeric associations in ring chromosome 19. Hum Genet 1993. 91: 42-44. (Pubitemid 23098526)
16. McGinniss, M. J., Kazazian, H. H., Jr., Stetten, G., Petersen, M. B., Boman, H., et al. Mechanisms of ring chromosome formation in 11 cases of human ring chromosome 21. Am J Hum Genet 1992. 50: 15-28.
17. Murnane, J. P. and Sabatier, L., Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. BioEssays 2004. 26: 1164-1174. (Pubitemid 39536612)
18. Arlt, M. F., Durkin, S. G., Ragland, R. L. and Glover, T. W., Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst) 2006. 5: 1126-1135. (Pubitemid 44376448)
19. Durkin, S. G. and Glover, T. W., Chromosome fragile sites. Annu Rev Genet 2007. 41: 169-192.
20. Arlt, M. F., Miller, D. E., Beer, D. G. and Glover, T. W., Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer 2002. 33: 82-92.
21. Rabbitts, T. H., Forster, A., Larson, R. and Nathan, P., Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993. 4: 175-180. (Pubitemid 23179103)
22. Bassing, C. H., Swat,W. and Alt, F. W., The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002. 109: S45-S55.
23. Viguera, E., Canceill, D. and Ehrlich, S. D., Replication slippage involves DNA polymerase pausing and dissociation. EMBO J 2001. 20: 2587-2595. (Pubitemid 32452877)
24. Abeysinghe, S. S., Chuzhanova, N. and Cooper, D. N., Gross deletions and translocations in human genetic disease. Genome Dyn 2006. 1: 17-34.
25. Grandin, N. and Charbonneau, M., Protection against chromosome degradation at the telomeres. Biochimie 2008. 90: 41-59. (Pubitemid 350216208)
26. Chabchoub, E., Rodriguez, L., Galan, E., Mansilla, E., Martinez-Fernandez, M. L., et al. Molecular characterisation of a mosaicism with a complex chromosome rearrangement: evidence for coincident chromosome healing by telomere capture and neo-telomere formation. J Med Genet 2007. 44: 250-256. (Pubitemid 46603617)
27. Chan, S. R. and Blackburn, E. H., Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci 2004. 359: 109-121.
28. Meltzer, P. S., Guan, X. Y. and Trent, J. M., Telomere capture stabilizes chromosome breakage. Nat Genet 1993. 4: 252-255.
29. Desmaze, C., Soria, J. C., Freulet-Marriere, M. A., Mathieu, N. and Sabatier, L., Telomere-driven genomic instability in cancer cells. Cancer Lett 2003. 194: 173-182. (Pubitemid 36577328)
30. Vos, L. J., Famulski, J. K. and Chan, G. K., How to build a centromere: from centromeric and pericentromeric chromatin to kinetochore assembly. Biochem Cell Biol 2006. 84: 619-639.
31. Choo, K. H., Vissel, B., Nagy, A., Earle, E. and Kalitsis, P., A survey of the genomic distribution of alpha satellite DNA on all the human chromosomes, and derivation of a new consensus sequence. Nucleic Acids Res 1991. 19: 1179-1182. (Pubitemid 21913201)
32. Marshall, O. J., Chueh, A. C., Wong, L. H. and Choo, K. H., Neocentromeres: new insights into centromere structure, disease development, and karyotype evolution. Am J Hum Genet 2008. 82: 261-282.
33. Choo, K. H., Centromere DNA dynamics: latent centromeres and neocentromere formation. Am J Hum Genet 1997. 61: 1225-1233.
34. Amor, D. J. and Choo, K. H., Neocentromeres: role in human disease, evolution, and centromere study. Am J Hum Genet 2002. 71: 695-714.
35. Voullaire, L. E., Slater, H. R., Petrovic, V. and Choo, K. H., A functional marker centromere with no detectable alpha-satellite, satellite III, or CENP-B protein: activation of a latent centromere? Am J Hum Genet 1993. 52: 1153-1163.
36. Sirvent, N., Forus, A., Lescaut, W., Burel, F., Benzaken, S., et al. Characterization of centromere alterations in liposarcomas. Genes Chromosomes Cancer 2000. 29: 117-129.
37. Italiano, A., Maire, G., Sirvent, N., Nuin, P. A., Keslair, F., et al. Variability of origin for the neocentromeric sequences in analphoid supernumerary marker chromosomes of well-differentiated liposarcomas. Cancer Lett 2009. 273: 323-330.
38. Deb, S. P., Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 2003. 1: 1009-1016.
39. Toledo, F. and Wahl, G. M., Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006. 6: 909-923. (Pubitemid 44862676)
40. Kuribayashi, K. and El-Deiry, W. S., Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 2008. 615: 201-221.
41. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E. and Sherr, C. J., Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993. 7: 331-342. (Pubitemid 23139228)
42. Weinberg, R. A., The retinoblastoma protein and cell cycle control. Cell 1995. 81: 323-330.
43. Patel, K. U., Szabo, S. S., Hernandez, V. S., Prieto, V.G., Abruzzo, L. V., et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008. 39: 184-193.
44. Simon, M. P., Navarro, M., Roux, D. and Pouyssegur, J., Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma protuberans (DP). Oncogene 2001. 20: 2965-2975.
45. Goldman, J. M. and Melo, J. V., BCR-ABL in chronic myelogenous leukemia - how does it work? Acta Haematol 2008. 119: 212-217.
46. Slack, J. L. and Gallagher, R. E., The molecular biology of acute promyelocytic leukemia. Cancer Treat Res 1999. 99: 75-124.
47. Micci, F., Panagopoulos, I., Haugom, L., Andersen, H. K., Tjonnfjord, G. E., et al. t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia. Cancer Lett 2009. 277: 205-211.
48. Kim, T. Y., Healy, K. D., Der, C. J., Sciaky, N., Bang, Y. J. and Juliano, R. L., Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. J Biol Chem 2008. 283: 32762-32770.
49. Morozova, O. and Marra, M. A., Applications of next-generation sequencing technologies in functional genomics. Genomics 2008. 92: 255-264.
50. Heng, H. H., Cancer genome sequencing: the challenges ahead. BioEssays 2007. 29: 783-794.
51. Bignell, G. R., Santarius, T., Pole, J. C., Butler, A. P., Perry, J., et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res 2007. 17: 1296-1303. (Pubitemid 47360904)
52. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007. 446: 153-158. (Pubitemid 46398669)
53. Campbell, P. J., Stephens, P. J., Pleasance, E. D., O'Meara, S., Li, H., et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 2008. 40: 722-729. (Pubitemid 351748860)
54. Maher, C. A., Kumar-Sinha, C., Cao, X., Kalyana-Sundaram, S., Han, B., et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009. 458: 97-101.
55. Mandelli, F., Diverio, D., Avvisati, G., Luciano, A., Barbui, T., et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997. 90: 1014-1021. (Pubitemid 27314135)
56. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996. 2: 561-566. (Pubitemid 26151518)
57. McArthur, G., Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004. 31: 30-36. (Pubitemid 38879420)
58. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001. 344: 783-792. (Pubitemid 32222155)